|
Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer. |
|
Elizabeth Charlotte Moser |
Employment - Elekta; Galera Therapeutics |
Leadership - Elekta; Galera Therapeutics |
Stock and Other Ownership Interests - Galera Therapeutics |
|
|
Honoraria - Varian Medical Systems |
Consulting or Advisory Role - IBA |
Speakers' Bureau - Varian Medical Systems |
Research Funding - Varian Medical Systems (Inst) |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
Employment - Wellcare (I) |
Honoraria - Boston Scientific |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - TYME; Xencor |
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen; Ipsen; Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Galera Therapeutics |
Stock and Other Ownership Interests - Galera Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; BTG; Celgene; Galera Therapeutics; Oncosil |
Speakers' Bureau - Boston Scientific; Bristol-Myers Squibb-Ono Pharmaceutical; BTG; Celgene |
Research Funding - Elekta (Inst); Galera Therapeutics |
Travel, Accommodations, Expenses - Abbvie; BTG |
|
|
Consulting or Advisory Role - Accuray |
Patents, Royalties, Other Intellectual Property - Oral amifostine for radio protection of the intestinal tract; PHD inhibitors for radio protection of the GI Tract |